Combination Antiviral Therapy with Lopinavir/Ritonavir, Arbidol and Interferon-α1b for COVID-19. Issue 4 (May 2020)

• Record Type: Journal Article
• Authors: Xie, Xiangyang; Jiang, Yuanliang; Zeng, Yuan; Liu, Hui
• Is Part Of: Antiviral therapy. Volume 25:Issue 4(2020)
• Page Start: 233
• Page End: 239
• Publication Date: 2020-05
• Subjects: Antiviral agents -- Periodicals; Antiviral Agents -- therapeutic use; Virus Diseases -- therapy; Viruses -- drug effects; Antiviral agents; Periodical; Electronic journals; Periodicals; 616.9106
• DOI: 10.3851/IMP3362
• Languages: English
• ISSNs: 1359-6535

Abstract

Since the outbreak of coronavirus disease (COVID-19) that was discovered in 2019 in Wuhan, China, no standard therapy guideline has been set despite the severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its high infectivity. The globally pandemic outbreak suggests that COVID-19 is highly infectious and difficult to control. A dual-combination of ribavirin and interferon-α has been the widely used regimen for the treatment of this disease in China. However, due to the varying results of treatment with these drugs, a novel antiviral combination therapy is urgently needed. This case reports the usage of lopinavir/ritonavir-based combination antiviral regimen for a patient with SARS-CoV-2 infection.